321 related articles for article (PubMed ID: 18569270)
1. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
2. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study.
Koo JY; Bagel J; Sweetser MT; Ticho BS
J Drugs Dermatol; 2006; 5(7):623-8. PubMed ID: 16865867
[TBL] [Abstract][Full Text] [Related]
3. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
[TBL] [Abstract][Full Text] [Related]
4. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
Ortonne JP; Khemis A; Koo JY; Choi J
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
6. An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept.
Magliocco MA; Lozano AM; Van Saders C; Schuler KW; Gottlieb AB
J Drugs Dermatol; 2007 Apr; 6(4):424-7. PubMed ID: 17668540
[TBL] [Abstract][Full Text] [Related]
7. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
Naldi L; Griffiths CE
Br J Dermatol; 2005 Apr; 152(4):597-615. PubMed ID: 15840088
[TBL] [Abstract][Full Text] [Related]
8. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
Scheinfeld N
J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
[TBL] [Abstract][Full Text] [Related]
9. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
[TBL] [Abstract][Full Text] [Related]
10. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.
Mease PJ; Reich K;
J Am Acad Dermatol; 2009 Mar; 60(3):402-11. PubMed ID: 19028407
[TBL] [Abstract][Full Text] [Related]
11. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Langewouters AM; Van Erp PE; De Jong EM; Van De Kerkhof PC
J Dermatolog Treat; 2006; 17(6):362-9. PubMed ID: 17853311
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
14. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
[TBL] [Abstract][Full Text] [Related]
15. Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study.
Searles G; Bissonnette R; Landells I; Shear NH; Papp K; Lui H
J Cutan Med Surg; 2009 Dec; 13 Suppl 3():S131-8. PubMed ID: 20053325
[TBL] [Abstract][Full Text] [Related]
16. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
Lowe NJ; Gonzalez J; Bagel J; Caro I; Ellis CN; Menter A
Int J Dermatol; 2003 Mar; 42(3):224-30. PubMed ID: 12653922
[TBL] [Abstract][Full Text] [Related]
17. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
[TBL] [Abstract][Full Text] [Related]
18. Alefacept modifies long-term disease severity and improves the response to other treatments.
van Duijnhoven MW; de Jong EM; Gerritsen WJ; Pasch MC; van de Kerkhof PC
Eur J Dermatol; 2005; 15(5):366-73. PubMed ID: 16172047
[TBL] [Abstract][Full Text] [Related]
19. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
Moul DK; Routhouska SB; Korman NJ
J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
[TBL] [Abstract][Full Text] [Related]
20. Clinical update on alefacept: consideration for use in patients with psoriasis.
Gade JN
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]